Brian Atwood
QuietNamed in filings at Versant AffiliatesOn the current fund
- Board seats filed
- 8
- Named on a board
- 0
all filings on record
Named in filings at Versant AffiliatesOn the current fund
all filings on record
last 24 months
from a verified or cited source
| CERO THERAPEUTICS HOLDINGS | Biotech & pharma | February 2024 | Versant Venture Capital |
| Cell Design Labs | Biotech & pharma | June 2016 | Versant Venture Capital, Vida Ventures, Westlake Biopartners |
| Atreca | Biotech & pharma | August 2015 | Versant Venture Capital |
| VERACYTE | Biotech & pharma | September 2014 | Versant Venture Capital, Vida Ventures |
| FIVE PRIME THERAPEUTICS | Biotech & pharma | March 2014 | Versant Venture Capital |
| PHASERX | Biotech & pharma | February 2012 | ARCH Venture Partners, Versant Venture Capital |
| OPGEN | Fintech | November 2011 | Highland Capital Partners, Versant Venture Capital |
| Immune Design | Biotech & pharma | February 2008 | The Column Group, Versant Venture Capital |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Brian Atwood on the board, based on 8 filed seats with a verified or cited source.